ArticleBJC reports2025
Interplay between AHR genotypes, lifestyle factors and adjuvant breast cancer treatments significantly impacts clinical outcome in a population-based cohort.
Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe purpose was to evaluate the prognostic impact of aryl hydrocarbon receptor (AHR) genotypes in relation to lifestyle and adjuvant treatments in breast cancer.
methodsAHR genotyping was performed on genomic DNA from 1701 patients included 2002-2016 in Lund, Sweden, and followed for up to 15 years. Eight AHR polymorphisms and eight haplotypes were analysed using survival and interaction analyses in relation to prognosis.
resultsHomozygosity for major allele frequencies was 42.1%-88.5%. AHR genotypes linked to lower AHR expression conferred differential prognosis combined with smoking, alcohol, antioxidant supplements, chemotherapy or endocrine therapy, with interactions between exposures and genotypes. Preoperative antioxidants combined with minor alleles of AHR_6 or AHR_9 conferred three-fold risks for breast cancer events, not seen in other patients (P
conclusionsThe prognostic impact of AHR genotypes depended on lifestyle and treatments, possibly due to the role of AhR as master regulator of metabolism, hypoxia, DNA repair and immune response. If confirmed, these findings may contribute to more personalised lifestyle recommendations and treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.